Compare Abeona Therapeutics Inc (ABEO) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Teucrium Wheat Fund — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Teucrium Wheat Fund trades at $22.85. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Teucrium Wheat Fund nearer its low. Which is the better fit depends on your goals.
| ABEO | WEAT | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $7.23 | $25.49 |
52-Week Low | $4.17 | $19.88 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
WEAT (Teucrium Wheat Fund) trades at $22.93, up 2.32% today, while technical indicators signal a bearish trend with moving averages showing sell pressure. The fund faces headwinds from reduced USDA wheat production forecasts and inflation concerns. Key support sits at $22 with resistance at $23, creating a tight trading range amid neutral oscillator readings.
Outlook remains cautious given agricultural commodity volatility and macroeconomic pressures. Investment opportunity exists for hedging against inflation, but risks include weather-dependent production and Federal Reserve policy impacts on commodity prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
